Trevi Therapeutics (TRVI) Competitors $14.18 +0.30 (+2.13%) As of 03:26 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI vs. IBRX, NUVL, PCVX, KYMR, and MIRMShould you buy Trevi Therapeutics stock or one of its competitors? MarketBeat compares Trevi Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trevi Therapeutics include ImmunityBio (IBRX), Nuvalent (NUVL), Vaxcyte (PCVX), Kymera Therapeutics (KYMR), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. TRVI vs. IBRXTRVI vs. NUVLTRVI vs. PCVXTRVI vs. KYMRTRVI vs. MIRMHow does Trevi Therapeutics compare to ImmunityBio?ImmunityBio (NASDAQ:IBRX) and Trevi Therapeutics (NASDAQ:TRVI) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Does the media refer more to IBRX or TRVI? In the previous week, ImmunityBio had 48 more articles in the media than Trevi Therapeutics. MarketBeat recorded 52 mentions for ImmunityBio and 4 mentions for Trevi Therapeutics. ImmunityBio's average media sentiment score of 0.16 beat Trevi Therapeutics' score of 0.00 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 7 Very Positive mention(s) 6 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, IBRX or TRVI? ImmunityBio has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Do institutionals and insiders have more ownership in IBRX or TRVI? 8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 69.5% of ImmunityBio shares are owned by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, IBRX or TRVI? Trevi Therapeutics has lower revenue, but higher earnings than ImmunityBio. Trevi Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$140.98M57.61-$351.40M-$0.85N/ATrevi TherapeuticsN/AN/A-$42.76M-$0.32N/A Is IBRX or TRVI more profitable? Trevi Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ImmunityBio-606.15% N/A -59.53% Trevi Therapeutics N/A -24.53%-23.37% Do analysts recommend IBRX or TRVI? ImmunityBio currently has a consensus price target of $14.20, suggesting a potential upside of 83.11%. Trevi Therapeutics has a consensus price target of $22.90, suggesting a potential upside of 59.80%. Given ImmunityBio's higher probable upside, equities research analysts clearly believe ImmunityBio is more favorable than Trevi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71Trevi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummaryTrevi Therapeutics beats ImmunityBio on 9 of the 16 factors compared between the two stocks.How does Trevi Therapeutics compare to Nuvalent?Trevi Therapeutics (NASDAQ:TRVI) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations. Do insiders & institutionals have more ownership in TRVI or NUVL? 95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts recommend TRVI or NUVL? Trevi Therapeutics presently has a consensus price target of $22.90, suggesting a potential upside of 59.80%. Nuvalent has a consensus price target of $137.25, suggesting a potential upside of 34.58%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Nuvalent 1 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.88 Which has more volatility and risk, TRVI or NUVL? Trevi Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Does the media refer more to TRVI or NUVL? In the previous week, Trevi Therapeutics had 3 more articles in the media than Nuvalent. MarketBeat recorded 4 mentions for Trevi Therapeutics and 1 mentions for Nuvalent. Trevi Therapeutics' average media sentiment score of 0.00 equaled Nuvalent'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, TRVI or NUVL? Trevi Therapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevi TherapeuticsN/AN/A-$42.76M-$0.32N/ANuvalentN/AN/A-$425.38M-$6.06N/A Is TRVI or NUVL more profitable? Trevi Therapeutics' return on equity of -24.53% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets Trevi TherapeuticsN/A -24.53% -23.37% Nuvalent N/A -40.11%-35.43% SummaryTrevi Therapeutics beats Nuvalent on 9 of the 13 factors compared between the two stocks.How does Trevi Therapeutics compare to Vaxcyte?Vaxcyte (NASDAQ:PCVX) and Trevi Therapeutics (NASDAQ:TRVI) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability. Do analysts recommend PCVX or TRVI? Vaxcyte currently has a consensus price target of $86.00, indicating a potential upside of 81.27%. Trevi Therapeutics has a consensus price target of $22.90, indicating a potential upside of 59.80%. Given Vaxcyte's higher probable upside, research analysts plainly believe Vaxcyte is more favorable than Trevi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63Trevi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media favor PCVX or TRVI? In the previous week, Vaxcyte and Vaxcyte both had 4 articles in the media. Vaxcyte's average media sentiment score of 0.49 beat Trevi Therapeutics' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in PCVX or TRVI? 96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 3.1% of Vaxcyte shares are held by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings & valuation, PCVX or TRVI? Trevi Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$766.63M-$6.88N/ATrevi TherapeuticsN/AN/A-$42.76M-$0.32N/A Which has more volatility & risk, PCVX or TRVI? Vaxcyte has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Is PCVX or TRVI more profitable? Trevi Therapeutics' return on equity of -24.53% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -32.51% -29.51% Trevi Therapeutics N/A -24.53%-23.37% SummaryTrevi Therapeutics beats Vaxcyte on 8 of the 13 factors compared between the two stocks.How does Trevi Therapeutics compare to Kymera Therapeutics?Kymera Therapeutics (NASDAQ:KYMR) and Trevi Therapeutics (NASDAQ:TRVI) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk. Does the media favor KYMR or TRVI? In the previous week, Kymera Therapeutics and Kymera Therapeutics both had 4 articles in the media. Kymera Therapeutics' average media sentiment score of 0.42 beat Trevi Therapeutics' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in KYMR or TRVI? 95.8% of Trevi Therapeutics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 18.3% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, KYMR or TRVI? Kymera Therapeutics has a beta of 2.06, meaning that its stock price is 106% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Do analysts recommend KYMR or TRVI? Kymera Therapeutics presently has a consensus price target of $118.10, indicating a potential upside of 46.95%. Trevi Therapeutics has a consensus price target of $22.90, indicating a potential upside of 59.80%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Trevi Therapeutics is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 1 Sell rating(s) 0 Hold rating(s) 20 Buy rating(s) 1 Strong Buy rating(s) 2.95Trevi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is KYMR or TRVI more profitable? Trevi Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Trevi Therapeutics' return on equity of -24.53% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-611.94% -24.71% -22.05% Trevi Therapeutics N/A -24.53%-23.37% Which has better earnings and valuation, KYMR or TRVI? Trevi Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$39.21M168.60-$311.35M-$3.57N/ATrevi TherapeuticsN/AN/A-$42.76M-$0.32N/A SummaryTrevi Therapeutics beats Kymera Therapeutics on 9 of the 15 factors compared between the two stocks.How does Trevi Therapeutics compare to Mirum Pharmaceuticals?Trevi Therapeutics (NASDAQ:TRVI) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability. Which has more risk and volatility, TRVI or MIRM? Trevi Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Do institutionals & insiders believe in TRVI or MIRM? 95.8% of Trevi Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 14.4% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is TRVI or MIRM more profitable? Trevi Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Trevi TherapeuticsN/A -24.53% -23.37% Mirum Pharmaceuticals -140.24%-11.28%-3.84% Do analysts recommend TRVI or MIRM? Trevi Therapeutics presently has a consensus price target of $22.90, indicating a potential upside of 59.80%. Mirum Pharmaceuticals has a consensus price target of $137.08, indicating a potential upside of 34.46%. Given Trevi Therapeutics' higher possible upside, analysts clearly believe Trevi Therapeutics is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Mirum Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media refer more to TRVI or MIRM? In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Trevi Therapeutics. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 4 mentions for Trevi Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 0.64 beat Trevi Therapeutics' score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, TRVI or MIRM? Mirum Pharmaceuticals has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevi TherapeuticsN/AN/A-$42.76M-$0.32N/AMirum Pharmaceuticals$521.31M11.93-$23.36M-$13.61N/A SummaryMirum Pharmaceuticals beats Trevi Therapeutics on 8 of the 14 factors compared between the two stocks. Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVI vs. The Competition ExportMetricTrevi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.03B$3.35B$6.33B$12.33BDividend YieldN/A2.32%2.80%5.36%P/E Ratio-44.7718.8920.8825.51Price / SalesN/A279.14520.5073.06Price / CashN/A125.3543.1855.00Price / Book11.846.9010.017.03Net Income-$42.76M$24.18M$3.54B$334.92M7 Day Performance-4.97%0.77%0.38%-0.40%1 Month Performance-1.98%-0.38%-0.02%1.07%1 Year Performance131.88%63.37%35.07%34.65% Trevi Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVITrevi Therapeutics2.9442 of 5 stars$14.18+2.1%$22.90+61.6%+114.5%$2.01BN/AN/A20Analyst ForecastIBRXImmunityBio3.0378 of 5 stars$8.08-0.6%$14.20+75.9%+177.6%$8.37B$113.29MN/A590Trending NewsAnalyst ForecastGap DownNUVLNuvalent2.3373 of 5 stars$102.78+0.2%$137.25+33.5%+34.8%$8.13BN/AN/A40PCVXVaxcyte2.8889 of 5 stars$54.31+0.5%$86.00+58.4%+29.0%$7.86BN/AN/A160KYMRKymera Therapeutics2.2531 of 5 stars$83.50-0.1%$118.10+41.4%+156.5%$6.88B$39.21MN/A170 Related Companies and Tools Related Companies IBRX Alternatives NUVL Alternatives PCVX Alternatives KYMR Alternatives MIRM Alternatives QGEN Alternatives SYRE Alternatives RYTM Alternatives TGTX Alternatives PTGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVI) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
